Incyte Corp. buy klostergang
Start price
26.06.17
/
50%
€121.30
Target price
29.10.18
€138.91
Performance (%)
-52.00%
End price
29.10.18
€58.23
Summary
This prediction ended on 29.10.18 with a price of €58.23. The BUY prediction by klostergang for Incyte Corp. performed very badly with a performance of -52.00%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Incyte Corp. | 5.010% | 5.010% | 50.014% | 84.834% |
| iShares Core DAX® | -1,06 % | 5,01 % | 6,60 % | 64,71 % |
| iShares Nasdaq 100 | -2,39 % | 0,86 % | 25,79 % | 88,24 % |
| iShares Nikkei 225® | -4,36 % | 1,21 % | 41,31 % | 79,31 % |
| iShares S&P 500 | -1,78 % | 1,39 % | 21,04 % | 69,60 % |
Comments by klostergang for this prediction
In the thread Incyte Corp. diskutieren
klostergang stimmt der Buy-Einschätzung von datca zu
klostergang stimmt am 26.06.2017 der Buy-Einschätzung von datca zu.
Überschrift: Incyte Corporation (INCY),-Kooperationen mit Novartis,Eli Lilly,Merck,MedImmune,Bristol-Myers Squibb,Genentech,Pfizer
(Laufzeit überschritten)